News and Announcements
SUDA Presents Data On Novel Penetration-Enhancing Technology
- Published November 17, 2016 3:23PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
17th November 2016
SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, today announced that Mr. Stephen Carter, Managing Director and CEO, presented data on the Company’s novel penetration-enhancing technology at the Annual Symposium of Drug Delivery Systems, being held on 16-19 November 2016 in Nanjing, China.
This scientific conference brings together scientists, academia, healthcare providers, policy makers and investors to provide insights into advances in drug delivery technologies. Mr. Carter chaired a session on “Tackling the Barriers in Different Routes of Drug Delivery.”
SUDA recently filed a provisional patent application with IP Australia for its novel mucosal penetration drug delivery technology. Mr. Carter presented data suggesting that the Company’s new technology, based on unique combinations of hydrotropes, can significantly enhance the permeation of active drugs through the oro-mucosal membrane into the blood system.
If you would like to download the full announcement, please click on the link below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
